Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
- Conditions
- Graft-versus-host Disease (GVHD)
- Registration Number
- NCT05722912
- Lead Sponsor
- Incyte Corporation
- Brief Summary
To provide ruxolitinib through an expanded access to treat a single patient with cGVHD
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- APPROVED_FOR_MARKETING
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method